Cingulate Inc. (NASDAQ:CINGW) Short Interest Update

Cingulate Inc. (NASDAQ:CINGW) was the recipient of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 5,920 shares, a growth of 705.4% from the July 30th total of 735 shares. Based on an average daily volume of 44,420 shares, the short-interest ratio is currently 0.1 days.

Cingulate Trading Down 28.0%

NASDAQ CINGW opened at $0.01 on Wednesday. The firm’s 50 day moving average price is $0.02 and its two-hundred day moving average price is $0.03. Cingulate has a twelve month low of $0.00 and a twelve month high of $0.12.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.